Compare Invesco DB Oil Fund (DBO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Novo Nordisk A/S — how do they compare? Invesco DB Oil Fund trades at $24.03 (market cap $255.13M), while Novo Nordisk A/S trades at $38.53 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 647.9× Invesco DB Oil Fund's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Invesco DB Oil Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Novo Nordisk A/S for 116 Days on average.
| DBO | NVO | |
|---|---|---|
Market Cap | $255.13M | $165.31B |
Volume | 562,167 | 11,432,838 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $63.98 |
52-Week Low | $11.98 | $35.29 |
Typical Hold Time | 31 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.
The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
